CA2421877A1 - Echangeurs a specificite de ligands/recepteurs permettant le reacheminement d'anticorps vers des recepteurs sur un agent pathogene - Google Patents

Echangeurs a specificite de ligands/recepteurs permettant le reacheminement d'anticorps vers des recepteurs sur un agent pathogene Download PDF

Info

Publication number
CA2421877A1
CA2421877A1 CA002421877A CA2421877A CA2421877A1 CA 2421877 A1 CA2421877 A1 CA 2421877A1 CA 002421877 A CA002421877 A CA 002421877A CA 2421877 A CA2421877 A CA 2421877A CA 2421877 A1 CA2421877 A1 CA 2421877A1
Authority
CA
Canada
Prior art keywords
seq
ligand
receptor
receptor specificity
specificity exchanger
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002421877A
Other languages
English (en)
Inventor
Matti Sallberg
Jan-Ingmar Flock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tripep AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2421877A1 publication Critical patent/CA2421877A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des compositions et des procédés de prévention et de traitement de maladies humaines comportant, mais de manière non exclusive, des agents pathogènes tels que les bactéries, les levures, les parasites, les champignons, les virus et le cancer. Plus particulièrement, les modes de réalisation de l'invention ont trait à la fabrication et à l'utilisation d'échangeurs à spécificité de ligands/récepteurs, permettant le réacheminement d'anticorps existant chez un sujet vers des récepteurs présents sur des agents pathogènes.
CA002421877A 2000-09-19 2001-09-19 Echangeurs a specificite de ligands/recepteurs permettant le reacheminement d'anticorps vers des recepteurs sur un agent pathogene Abandoned CA2421877A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66402500A 2000-09-19 2000-09-19
US09/664,025 2000-09-19
PCT/IB2001/002327 WO2002024887A2 (fr) 2000-09-19 2001-09-19 Echangeurs a specificite de ligands/recepteurs permettant le reacheminement d'anticorps vers des recepteurs sur un agent pathogene

Publications (1)

Publication Number Publication Date
CA2421877A1 true CA2421877A1 (fr) 2002-03-28

Family

ID=24664202

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002421877A Abandoned CA2421877A1 (fr) 2000-09-19 2001-09-19 Echangeurs a specificite de ligands/recepteurs permettant le reacheminement d'anticorps vers des recepteurs sur un agent pathogene

Country Status (9)

Country Link
EP (1) EP1354033A2 (fr)
JP (1) JP2004509621A (fr)
KR (1) KR20030034194A (fr)
CN (1) CN100371442C (fr)
AU (2) AU2397302A (fr)
CA (1) CA2421877A1 (fr)
PL (1) PL364788A1 (fr)
RU (1) RU2300391C2 (fr)
WO (1) WO2002024887A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US7052849B2 (en) * 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
EP2230249A3 (fr) 2003-02-06 2010-12-22 ChronTech Pharma AB Antigène/anticorps ou ligand/récepteur glycosyles avec un échangeur de spécificité
EP2486408A4 (fr) 2009-10-05 2013-04-24 Opsonic Therapeutics Inc Molécules adaptatrices de haute affinité pour rediriger la spécificité d'anticorps
CN101987866B (zh) * 2010-10-25 2013-01-23 中国人民解放军军事医学科学院基础医学研究所 金黄色葡萄球菌Efb蛋白C端抗原表位及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04310861A (ja) * 1991-04-09 1992-11-02 Kazuo Yanagi 抗ebna抗体の測定方法および抗ebna抗体測定キット
EP0744891B1 (fr) * 1994-02-18 2007-10-03 The American National Red Cross Fibrinogene transgenique
SE9401460D0 (sv) * 1994-04-28 1994-04-28 Ferring Ab Antigen/antibody specificity exhanger
DE69938130T2 (de) * 1998-05-27 2009-03-12 Hadasit Medical Research Services & Development Co. Ltd. Neue peptide
PT1119630E (pt) * 1998-11-05 2006-05-31 Powderject Vaccines Inc Construcoes de acido nucleico para imunizacao genetica

Also Published As

Publication number Publication date
WO2002024887A2 (fr) 2002-03-28
AU2002223973B2 (en) 2007-04-05
JP2004509621A (ja) 2004-04-02
AU2397302A (en) 2002-04-02
RU2003106428A (ru) 2005-01-20
KR20030034194A (ko) 2003-05-01
EP1354033A2 (fr) 2003-10-22
CN1476476A (zh) 2004-02-18
PL364788A1 (en) 2004-12-13
WO2002024887A3 (fr) 2003-08-14
RU2300391C2 (ru) 2007-06-10
CN100371442C (zh) 2008-02-27

Similar Documents

Publication Publication Date Title
US6933366B2 (en) Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US6660842B1 (en) Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
AU2012200059B2 (en) "Antigen/antibody or ligand/receptor glycosylated"
JP4216473B2 (ja) Hiv感染および免疫疾患の予防および治療のペプチド組成物
US5204259A (en) Methods and systems for producing HIV antigens
CA2091263C (fr) Peptides utilises pour la vaccination et l'induction d'anticorps neutralisants contre le virus de l'immunodeficience humaine
HU214439B (hu) Eljárás HIV-fertőzések kezelésére alkalmas monoklonális antitestek és peptidek, valamint ezeket tartalmazó gyógyászati készítmények és vakcinák előállítására
AU2002223973B2 (en) Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
AU2002223973A1 (en) Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US6827939B2 (en) Peptide having an affinity for gp120
US7534435B2 (en) Glycosylated specificity exchangers
AU2007203138B2 (en) Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
EP0343132A2 (fr) Procédés et méthodes de production d'antigènes HIV
CA2058876A1 (fr) Peptides cycliques, principaux determinants de neutralisation du vih

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150205